Loading, Please Wait...
ST. LOUIS, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the second quarter ended June 30, 2019. In a separate press release issued concurrently with this release, Stereotaxis announced a $25 million private placement equity financing.
“The second quarter was an exciting period for Stereotaxis and a pivotal turning point in our effort to reestablish a long-term growth trajectory,” said David Fischel, Chairman and CEO. “Since showcasing our innovation accomplishments and strategy at the Heart Rhythm Society conference in May, many existing and potential customers have visited our headquarters to view our innovations first hand. The broad, enthusiastic response validates that our innovation and strategic decisions were sound and that our plan is medically and commercially attractive. We are confident in our expectation for significant revenue growth in the years ahead.”
As mentioned previously, in the second quarter Stereotaxis announced several innovation accomplishments and programs:
David Fischel continued, “With the financing announced today, Stereotaxis has the financial strength to accelerate the development and commercial introduction of these innovations, as well as to fund a second wave of innovations in electrophysiology and beyond.”
Second Quarter 2019 Financial Results
Revenue for the second quarter of 2019 totaled $6.8 million compared to $7.6 million in the prior year second quarter. This decrease was primarily due to reduced service revenue from system moves as well as certain inactive accounts that have aged and no longer maintain active service contracts, partially offset by a modest increase in procedure volume compared to the prior year second quarter.
Gross margin in the quarter was 83% of revenue, consistent with the 82% reported in the second quarter of 2018. Operating expenses in the second quarter of $7.1 million increased from $6.8 million in the prior year quarter. The increase in operating expenses reflects significantly increased investment in research and development with reduced general, administrative and selling expenses.
Operating loss and net loss in the second quarter were ($1.5) million and ($1.4) million, respectively, compared to ($0.6) million for both in 2018. Negative free cash flow for the quarter was ($0.5) and was consistent with previously provided guidance for 2019.
Cash Balance and Liquidity
At June 30, 2019, Stereotaxis had cash and cash equivalents of $8.5 million and no debt. Pro forma, including the financing announced today and deducting financing related fees and expenses, Stereotaxis would have held approximately $31.6 million in cash and cash equivalents as of June 30, 2019 with a stockholders’ equity balance of $21.8 million.
Full Year 2019 Expectations
Stereotaxis’ innovation accomplishments support an expectation of robust and consistent overall revenue growth beginning in the coming quarters and accelerating throughout 2020.
Without considering the financing announced today, Stereotaxis would have reiterated its expectation to end 2019 with greater than $6.0 million in net cash and to reach profitability without the need for additional capital.
Conference Call and Webcast
Stereotaxis will host a conference call and webcast today, August 8, 2019, at 9:00 a.m. Eastern Time. To access the conference call, dial 1-800-353-6461 (US and Canada) or 1-334-323-0501 (International) and give the participant pass code 2198862. Participants are asked to call 5-10 minutes prior to the start time. To access the live and replay webcast, please visit the investor relations section of the Stereotaxis website at www.stereotaxis.com.
Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis’ robotic technology has received various regulatory clearances in the United States, European Union, Japan, Canada, China, and elsewhere. The Stereotaxis Genesis RMN System is CE marked and will become available in other global geographies subject to regulatory approvals. Stereotaxis Imaging Model S is CE marked and FDA cleared. For more information, please visit www.stereotaxis.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness, or to obtain additional financing, in either case on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from healthcare reform in the United States, including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.
David L. Fischel
Chairman and Chief Executive Officer
Martin C. Stammer
Chief Financial Officer
|STATEMENTS OF OPERATIONS|
Three Months Ended
Six Months Ended
|Disposables, service and accessories||6,546,115||7,240,650||13,256,873||14,195,008|
|Cost of revenue:|
|Disposables, service and accessories||894,760||931,541||2,009,119||1,993,286|
|Total cost of revenue||1,147,492||1,389,050||2,559,545||2,654,397|
|Research and development||2,695,162||2,032,394||5,654,381||3,995,020|
|Sales and marketing||3,236,516||3,457,416||6,546,342||7,092,413|
|General and administrative||1,178,469||1,298,604||2,646,629||2,537,783|
|Total operating expenses||7,110,147||6,788,414||14,847,352||13,625,216|
|Interest income (expense)||31,810||(6,142||)||48,374||(30,757||)|
|Net income (loss)||$||(1,427,718||)||$||(632,205||)||$||(3,550,538||)||$||803,025|
|Cumulative dividend on convertible preferred stock||(357,194||)||(357,518||)||(710,704||)||(711,107||)|
|Net income attributable to convertible preferred stock||-||-||(42,936||)|
|Net income (loss) attributable to common stockholders||$||(1,784,912||)||$||(989,723||)||$||(4,261,242||)||$||48,982|
|Net income (loss) per share attributed to common stockholder:|
|Weighted average number of common shares and equivalents:|
|Cash and cash equivalents||$||8,471,914||$||10,796,072|
|Accounts receivable, net of allowance of $502,251 and $398,847 in 2019 and 2018, respectively||4,997,148||5,021,111|
|Prepaid expenses and other current assets||514,408||963,700|
|Total current assets||15,543,586||17,972,549|
|Property and equipment, net||297,494||343,693|
|Operating lease right-of-use assets||5,245,842||-|
|Liabilities and stockholders' equity (deficit)|
|Current portion of operating lease liabilities||2,223,023||-|
|Total current liabilities||12,779,118||10,194,377|
|Long-term deferred revenue||508,772||407,151|
|Operating lease liabilities||3,048,650||-|
|Convertible preferred stock:|
|Convertible preferred stock, par value $0.001; 10,000,000 shares authorized, 23,855 and 23,900 shares outstanding at 2019 and 2018||5,948,953||5,960,475|
|Stockholders' equity (deficit):|
|Common stock, par value $0.001; 300,000,000 shares authorized, 59,383,038 and 59,058,297 shares issued at 2019 and 2018, respectively||59,383||59,058|
|Additional paid-in capital||479,127,279||478,179,574|
|Treasury stock, 4,015 shares at 2019 and 2018||(205,999||)||(205,999||)|
|Total stockholders' equity (deficit)||(1,291,365||)||1,311,143|
|Total liabilities and stockholders' equity (deficit)||$||21,255,075||$||18,514,607|